Given the potent inflammatory potential of NLRP3 and its role in NASH pathogenesis, targeting NLRP3 inflammasome has been proven to be an attractive pharmacological approach for the pharmacotherapy of NASH. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.